Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy
Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy
复制标题
DOI：
10.1016/j.ajo.2006.02.015
复制
发表时间：
2006-07-01
影响因子：
4.2
通讯作者：
Tano, Yasuo
中科院分区：
文献类型：
--
作者：
Oshima, Yusuke;Sakaguchi, Hirokazu;Tano, Yasuo
目的：评价玻璃体内注射贝伐单抗治疗虹膜新生血管（INV）的短期安全性和有效性。设计：非比较性干预性病例系列。方法：对5例伴有增殖性糖尿病视网膜病变（PDR）的INV患者的7只眼进行玻璃体内注射贝伐单抗。注射前、注射后1周、注射后1个月、注射后2个月的主要测量指标为视力、眼内压（IOP）和荧光素血管造影的INV消退。结果：注射后1周，所有眼（100%）INV均恢复。首次注射后2个月，反复注射可稳定复发（2只眼，29%）。随访期间，6只眼（86%）的视力保持稳定或改善，眼压得到控制。无炎症及并发症。结论：对于常规治疗难治性INV患者，玻璃体内注射贝伐单抗可能是一种有效且安全的替代方案。
PURPOSE: To assess the short,term safety and efficacy of intravitreal injection of bevacizumab for iris neovascularization (INV).DESIGN: Noncomparative, interventional case series.METHODS: Intravitreal bevacizumab was injected in seven eyes of five patients with INV that was associated with proliferative diabetic retinopathy (PDR). The main out, come measurements were visual acuity, intraocular pressure (IOP), and regression of INV by fluorescein angiography before and one week, one month, and two months after injection.RESULTS: Regression of INV was confirmed in all eyes (100%) from one week after injection. Repeated injections stabilized the recurrence (two eyes; 29%) that was observed two months after the initial injection. The visual acuity remained stable or improved, and the intraocular pressure was controlled in six eyes (86%) throughout the follow,up period. No inflammation or complications were observed.CONCLUSIONS: Intravitreal injection of bevacizumab may be an effective and safe alternative for patients with INV that is refractory to conventional treatments.